Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature and heart rate were measured in semi-supine position after 5 minutes rest. The PCI ranges for vitals were as follows; for SBP <85 or >160 millimeters of mercury (mmHg), for DBP <45 or >100 mmHg, for heart rate <40 or >110 beats per minute and for temperature <36 or >38 Celsius. The number of participants with vital signs of PCI have been presented.

Twelve-lead ECGs were performed during the study using an automated ECG machine, after 5 minutes of rest. The number of participants with abnormal ECG findings were reported and categorized as clinically significant and not clinically significant. Any value for ECG parameters out of the following normal range was considered as clinically significant abnormality; for PR interval <110 or >220 milliseconds, for QRS interval <75 or >110 milliseconds and for QT corrected interval <450 milliseconds.

Blood samples were collected for analysis of clinical chemistry parameters. The PCI ranges were for Albumin <30 millimoles/Liter (mmol/L), Calcium (<2 or >2.75 mmol/L), Creatinine (>44.2 mmol/L), Glucose (<3 or >9 mmol/L), Magnesium (<0.5 or >1.23 mmol/L), Phosphorus (<0.8 or > 1.6 mmol/L), Potassium (<3 or > 5.5 mmol/L), Sodium (<130 or 150 mmol/L), Total carbon-dioxide (<18 or > 32 mmol/L), Alanine aminotransferase (>= 2x Upper Limit of Normal [ULN]), Aspartate aminotransferase (>=2x ULN), alkaline phosphatase (>=2x ULN), and total bilirubin (>=1.5xULN). The number of participants with values for clinical chemistry parameters of PCI have been presented

Blood samples were collected for analysis of hematology parameters. PCI ranges were for platelets (< 50 or >550 × 10^9 cells/L), white blood cell count (<3 or >14 × 10^9 cells/L), hemoglobin (<90 or >180 g/L), hematocrit (if proportion of red blood cells in blood was <0.3 or >0.54), lymphocytes (<0.5 × 10^9 cells/L), neutrophils (<1.0 × 10^9 cells/L) and monocytes (<0.2 or 1.5 × 10^9 cells/L). The number of participants with values for hematology parameters of PCI have been presented.

Urine samples were collected for the analysis of specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones at specified time points. The number of participants with abnormal urinalysis findings have been presented.

A participant was considered to be a responder according to the ACR20 criteria if the participant had at least 20% improvement in both the tender joint count and swollen joint count measures, and 20% improvement in at least 3 of the following 5 measures: patient and physician global assessments, pain, disability, and an acute-phase reactant. This analysis was planned but data was not collected , as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

A participant was considered to be a responder according to the ACR50 criteria if the participant had at least 50% improvement in both the tender joint count and swollen joint count measures, and 50% improvement in at least 3 of the following 5 measures: patient and physician global assessments, pain, disability, and an acute-phase reactant. This analysis was planned but data was not collected , as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

A participant was considered to be a responder according to the ACR70 criteria if the participant had at least 70% improvement in both the tender joint count and swollen joint count measures, and 70% improvement in at least 3 of the following 5 measures: patient and physician global assessments, pain, disability, and an acute-phase reactant. This analysis was planned but data was not collected , as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

The total number of joints ranging from 0 to 28 joints with a present swelling were assessed. The following 28 joints were taken into account for SJC28: Shoulder (2 joints), Knee (2), Elbow (2), Wrist (2), Fingers (Joints for proximal interphalangeal [PIP] and metacarpophalangeal [MCP]: 20). No missing observations were considered. Individual participant data has been presented. Only data available at specified visit with respect to the participant has been presented.

The total number of joints ranging from 0 to 28 joints with a present tenderness were assessed. The following 28 joints were taken into account for TJC28: Shoulder (2 joints), Knee (2), Elbow (2), Wrist (2), Fingers (PIP and MCP: 20). No missing observations were considered. Individual participant data has been presented. Only data available at specified visit with respect to the participant has been presented.

The DAS28 score is a derived measurement with differential weighing given to each component as: TJC28 and SJC28 both scored 0-28 (higher scores indicate higher disease activity), CRP measured in milligrams per liter and PtGA (visual analogue scale with values from 0 [best] to 100 [worst]). The formula used to calculate DAS28 score was 0.56 multiplied by square root of TJC28 plus 0.28 multiplied by square root of SJC28 plus 0.36 log of (CRP plus 1) plus 0.014 multiplied by PtGA plus 0.96. DAS28 scores ranged from 0 (best) to 10 (worst). A negative change from Baseline value indicated improvement. Baseline was defined at Day 1 (pre-dose). Change from Baseline was post-baseline value minus the value at Baseline. Only data available at specified visit with respect to the participant has been presented.

Participants completed the global assessment of disease activity using the PtGA item using visual analogue scale (VAS) ranging from "0" (none) to "100" (extremely active), respectively. Individual participant score has been presented. Only data available at specified visit with respect to the participant has been presented.

Blood samples were collected at indicated time points for the analysis of CRP. Change from Baseline, was defined as the post-baseline value minus the value at Baseline. Baseline was defined as the value from the Day 1 (pre-dose). Individual participant data has been presented. Only data available at specified visit with respect to the participant has been presented.

Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified timepoints. The Pharmacokinetic (PK) Population was defined as participants in the Safety Population who received an active dose and for whom a PK sample was obtained and analyzed. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Cmax was defined as the maximum concentration of drug in the plasma. Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified time points. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Tmax was defined as time required to achieve Cmax for drug, in the plasma. Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were planned to be collected for GSK3117391, and its acid metabolite GSK3339189, at the specified time points. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were planned to be collected for GSK3117391, and its acid metabolite GSK3339189, at the specified timepoints. Accumulation ratio was planned to be determined from the ratio of AUC from time zero to time of next dosing (AUC [0-tau]) following single dose administration /AUC (0-tau) on repeat dose administration. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

CL/F, describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). Blood samples, were planned to be collected for GSK3117391, and its acid metabolite GSK3339189, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

V/F, is defined as the theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the blood plasma. Blood samples, were planned to be collected for GSK3117391, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were collected at the indicated time points for the analysis of monocytes. Change from Baseline was defined as the post-Baseline value minus the value at Baseline. Baseline was defined as the value from the Day 1 (pre-dose). Individual participant data has been presented. Only data available at specified visit with respect to the participant has been presented.

Change from Baseline, was defined as the post-Baseline value minus the value at Baseline. Baseline was defined as the value from the Day 1 (pre-dose). Blood samples were planned to be analyzed by flow cytometry for cell markers to determine any changes after treatment with GSK3117391. This analysis was planned but the assay was not performed due to sample size being too small at the time of early study termination.

Blood samples were collected at the indicated time points and analyzed by flow cytometry for cell markers to determine any changes after treatment with GSK3117391. Change from Baseline was defined as the post-Baseline value minus the value at Baseline. Baseline was defined as the value from the Day 1 (pre-dose). Individual participant data has been presented. Only data available at specified visit with respect to the participant has been presented.

Total of all reporting groups

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth defect and other situations which involve medical or scientific judgment, and is associated with liver injury and impaired liver function.

Safety Population.

Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature and heart rate were measured in semi-supine position after 5 minutes rest. The PCI ranges for vitals were as follows; for SBP <85 or >160 millimeters of mercury (mmHg), for DBP <45 or >100 mmHg, for heart rate <40 or >110 beats per minute and for temperature <36 or >38 Celsius. The number of participants with vital signs of PCI have been presented.

Safety Population

Twelve-lead ECGs were performed during the study using an automated ECG machine, after 5 minutes of rest. The number of participants with abnormal ECG findings were reported and categorized as clinically significant and not clinically significant. Any value for ECG parameters out of the following normal range was considered as clinically significant abnormality; for PR interval <110 or >220 milliseconds, for QRS interval <75 or >110 milliseconds and for QT corrected interval <450 milliseconds.

Safety Population

Blood samples were collected for analysis of clinical chemistry parameters. The PCI ranges were for Albumin <30 millimoles/Liter (mmol/L), Calcium (<2 or >2.75 mmol/L), Creatinine (>44.2 mmol/L), Glucose (<3 or >9 mmol/L), Magnesium (<0.5 or >1.23 mmol/L), Phosphorus (<0.8 or > 1.6 mmol/L), Potassium (<3 or > 5.5 mmol/L), Sodium (<130 or 150 mmol/L), Total carbon-dioxide (<18 or > 32 mmol/L), Alanine aminotransferase (>= 2x Upper Limit of Normal [ULN]), Aspartate aminotransferase (>=2x ULN), alkaline phosphatase (>=2x ULN), and total bilirubin (>=1.5xULN). The number of participants with values for clinical chemistry parameters of PCI have been presented

Safety Population

Blood samples were collected for analysis of hematology parameters. PCI ranges were for platelets (< 50 or >550 × 10^9 cells/L), white blood cell count (<3 or >14 × 10^9 cells/L), hemoglobin (<90 or >180 g/L), hematocrit (if proportion of red blood cells in blood was <0.3 or >0.54), lymphocytes (<0.5 × 10^9 cells/L), neutrophils (<1.0 × 10^9 cells/L) and monocytes (<0.2 or 1.5 × 10^9 cells/L). The number of participants with values for hematology parameters of PCI have been presented.

Safety Population

Urine samples were collected for the analysis of specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones at specified time points. The number of participants with abnormal urinalysis findings have been presented.

Safety Population

A participant was considered to be a responder according to the ACR20 criteria if the participant had at least 20% improvement in both the tender joint count and swollen joint count measures, and 20% improvement in at least 3 of the following 5 measures: patient and physician global assessments, pain, disability, and an acute-phase reactant. This analysis was planned but data was not collected , as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Safety Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

A participant was considered to be a responder according to the ACR50 criteria if the participant had at least 50% improvement in both the tender joint count and swollen joint count measures, and 50% improvement in at least 3 of the following 5 measures: patient and physician global assessments, pain, disability, and an acute-phase reactant. This analysis was planned but data was not collected , as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Safety Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

A participant was considered to be a responder according to the ACR70 criteria if the participant had at least 70% improvement in both the tender joint count and swollen joint count measures, and 70% improvement in at least 3 of the following 5 measures: patient and physician global assessments, pain, disability, and an acute-phase reactant. This analysis was planned but data was not collected , as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Safety Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

The total number of joints ranging from 0 to 28 joints with a present swelling were assessed. The following 28 joints were taken into account for SJC28: Shoulder (2 joints), Knee (2), Elbow (2), Wrist (2), Fingers (Joints for proximal interphalangeal [PIP] and metacarpophalangeal [MCP]: 20). No missing observations were considered. Individual participant data has been presented. Only data available at specified visit with respect to the participant has been presented.

Safety Population. Only those participants with data available at specified time point has been analyzed (represented by n=x in category titles). Data has been presented for participants as per the actual treatment received.

The total number of joints ranging from 0 to 28 joints with a present tenderness were assessed. The following 28 joints were taken into account for TJC28: Shoulder (2 joints), Knee (2), Elbow (2), Wrist (2), Fingers (PIP and MCP: 20). No missing observations were considered. Individual participant data has been presented. Only data available at specified visit with respect to the participant has been presented.

Safety Population. Only those participants with data available at specified time point has been analyzed (represented by n=x in category titles). Data has been presented for participants as per the actual treatment received.

The DAS28 score is a derived measurement with differential weighing given to each component as: TJC28 and SJC28 both scored 0-28 (higher scores indicate higher disease activity), CRP measured in milligrams per liter and PtGA (visual analogue scale with values from 0 [best] to 100 [worst]). The formula used to calculate DAS28 score was 0.56 multiplied by square root of TJC28 plus 0.28 multiplied by square root of SJC28 plus 0.36 log of (CRP plus 1) plus 0.014 multiplied by PtGA plus 0.96. DAS28 scores ranged from 0 (best) to 10 (worst). A negative change from Baseline value indicated improvement. Baseline was defined at Day 1 (pre-dose). Change from Baseline was post-baseline value minus the value at Baseline. Only data available at specified visit with respect to the participant has been presented.

Safety Population. Only those participants with data available at specified time point has been analyzed (represented by n=x in category titles). Data has been presented for participants as per the actual treatment received.

Participants completed the global assessment of disease activity using the PtGA item using visual analogue scale (VAS) ranging from "0" (none) to "100" (extremely active), respectively. Individual participant score has been presented. Only data available at specified visit with respect to the participant has been presented.

Safety Population. Only those participants with data available at specified time point has been analyzed (represented by n=x in category titles). Data has been presented for participants as per the actual treatment received.

Blood samples were collected at indicated time points for the analysis of CRP. Change from Baseline, was defined as the post-baseline value minus the value at Baseline. Baseline was defined as the value from the Day 1 (pre-dose). Individual participant data has been presented. Only data available at specified visit with respect to the participant has been presented.

Safety Population. Only those participants with data available at specified time point has been analyzed (represented by n=x in category titles). Data has been presented for participants as per the actual treatment received.

Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified timepoints. The Pharmacokinetic (PK) Population was defined as participants in the Safety Population who received an active dose and for whom a PK sample was obtained and analyzed. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

PK Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Cmax was defined as the maximum concentration of drug in the plasma. Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified time points. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

PK Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Tmax was defined as time required to achieve Cmax for drug, in the plasma. Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

PK Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were planned to be collected for GSK3117391, and its acid metabolite GSK3339189, at the specified time points. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

PK Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

PK Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

PK Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

PK Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were planned to be collected for GSK3117391 and its acid metabolite GSK3339189, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

PK Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were planned to be collected for GSK3117391, and its acid metabolite GSK3339189, at the specified timepoints. Accumulation ratio was planned to be determined from the ratio of AUC from time zero to time of next dosing (AUC [0-tau]) following single dose administration /AUC (0-tau) on repeat dose administration. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

PK Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

CL/F, describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). Blood samples, were planned to be collected for GSK3117391, and its acid metabolite GSK3339189, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

PK Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

V/F, is defined as the theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the blood plasma. Blood samples, were planned to be collected for GSK3117391, at the specified timepoints. This analysis was planned but was not performed as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

PK Population. Data was not collected, as the sample size was too small and study was terminated pre-maturely, by the sponsor following internal review.

Blood samples were collected at the indicated time points for the analysis of monocytes. Change from Baseline was defined as the post-Baseline value minus the value at Baseline. Baseline was defined as the value from the Day 1 (pre-dose). Individual participant data has been presented. Only data available at specified visit with respect to the participant has been presented.

Safety Population. Only those participants with data available at specified time point has been analyzed (represented by n=x in category titles). Data has been presented for participants as per the actual treatment received.

Change from Baseline, was defined as the post-Baseline value minus the value at Baseline. Baseline was defined as the value from the Day 1 (pre-dose). Blood samples were planned to be analyzed by flow cytometry for cell markers to determine any changes after treatment with GSK3117391. This analysis was planned but the assay was not performed due to sample size being too small at the time of early study termination.

Safety Population. Data was not collected, assay was not performed due to sample size being too small at the time of early study termination.

Blood samples were collected at the indicated time points and analyzed by flow cytometry for cell markers to determine any changes after treatment with GSK3117391. Change from Baseline was defined as the post-Baseline value minus the value at Baseline. Baseline was defined as the value from the Day 1 (pre-dose). Individual participant data has been presented. Only data available at specified visit with respect to the participant has been presented.

Safety Population. Only those participants with data available at specified time point has been analyzed (represented by n=x in category titles). Data has been presented for participants as per the actual treatment received.

Eligible participants in this arm, received a dose of 40 mg of GSK3117391, administered orally once a day as 2 capsules of 20 mg each in the morning, following every other day, for 28-days.